Cargando…

Biofabrication of an in-vitro bone model for Gaucher disease

Gaucher disease (GD), the most prevalent lysosomal disorder, is caused by GBA1 gene mutations, leading to deficiency of glucocerebrosidase, and accumulation of glycosphingolipids in cells of the mononuclear phagocyte system. While skeletal diseases are the leading cause of morbidity and reduced qual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banerjee, Dishary, Ivanova, Margarita M, Celik, Nazmiye, Kim, Myoung Hwan, Derman, Irem Deniz, Limgala, Renuka Pudi, Ozbolat, Ibrahim T, Goker-Alpan, Ozlem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOP Publishing 2023
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515412/ https://www.ncbi.nlm.nih.gov/pubmed/37703870 http://dx.doi.org/10.1088/1758-5090/acf95a

Ejemplares similares

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants
por: Limgala, Renuka Pudi, et al.
Publicado: (2021)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Aspiration-assisted freeform bioprinting of prefabricated tissue spheroids in a yield-stress gel
por: Ayan, Bugra, et al.
Publicado: (2020)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

High-throughput microgel biofabrication via air-assisted co-axial jetting for cell encapsulation, 3D bioprinting, and scaffolding applications
por: Pal, Vaibhav, et al.
Publicado: (2023)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

Synergistic coupling between 3D bioprinting and vascularization strategies
por: Yeo, Miji, et al.
Publicado: (2024)

129. Micropuncture Vascularization of Intraoperative Bioprinted Scaffolds
por: Horchler, Summer, et al.
Publicado: (2023)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

A Pilot Study of Omalizumab in Eosinophilic Esophagitis
por: Loizou, Denise, et al.
Publicado: (2015)

Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy
por: Ivanova, Margarita M., et al.
Publicado: (2023)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy
por: Ivanova, Margarita M., et al.
Publicado: (2020)

Polymer Nanocomposites of Selenium Biofabricated Using Fungi
por: Tsivileva, Olga, et al.
Publicado: (2021)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases
por: Ivanova, Margarita
Publicado: (2020)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Intraoperative bioprinting of human adipose-derived stem cells and extra-cellular matrix induces hair follicle-like downgrowths and adipose tissue formation during full-thickness craniomaxillofacial skin reconstruction
por: Kang, Youngnam, et al.
Publicado: (2023)

Gaucher disease – bone involvement
por: Chis, Bogdan Augustin, et al.
Publicado: (2021)

Biofabrication and Bone Tissue Regeneration: Cell Source, Approaches, and Challenges
por: Orciani, Monia, et al.
Publicado: (2017)

Biofabrication of Prevascularised Hypertrophic Cartilage Microtissues for Bone Tissue Engineering
por: Nulty, Jessica, et al.
Publicado: (2021)

In Vitro Biofabrication of Tissues and Organs
por: Nakayama, Koichi
Publicado: (2013)

Enhancing Peptide Biomaterials for Biofabrication
por: Firipis, Kate, et al.
Publicado: (2021)

Biofabrication of nanovesicles for brain diseases
por: Picone, Pasquale, et al.
Publicado: (2022)

Biofabrication of natural hydrogels for cardiac, neural, and bone Tissue engineering Applications
por: Elkhoury, Kamil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0hf437quo6h3067u6dh23nk1d6